pyrazines has been researched along with vorinostat in 53 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (28.30) | 29.6817 |
| 2010's | 38 (71.70) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, J; Elliott, PJ | 1 |
| Conrad, D; Dent, P; Grant, S; Rahmani, M; Subler, M; Yu, C | 1 |
| Dai, Y; Grant, S; Pei, XY | 1 |
| Denlinger, CE; Jones, DR; Rundall, BK | 1 |
| Abbruzzese, JL; Andtbacka, RH; Bornmann, WG; Carew, JS; Chiao, PJ; Dunner, K; Highshaw, RA; Huang, P; McConkey, DJ; Nawrocki, ST; Pal, A; Pino, MS; Xiong, H | 1 |
| Carlisi, D; D'Anneo, A; Di Fazio, P; Emanuele, S; Lauricella, M; Tesoriere, G; Vassallo, B; Vento, R | 1 |
| Buda, G; Canestraro, M; Fazzi, R; Galimberti, S; Guerrini, F; Khan, R; Maffei, R; Marasca, R; Orciuolo, E; Petrini, M | 1 |
| Fleissner, C; Heider, U; Jakob, C; Kaiser, M; Kloetzel, PM; Kuckelkorn, U; Rademacher, J; Rosche, M; Rötzer, S; Sezer, O; Sterz, J; von Metzler, I | 1 |
| Carew, JS; Cleveland, JL; Courage, JF; Giles, FJ; Houghton, JA; Huang, P; Maclean, KH; McConkey, DJ; Nawrocki, ST | 1 |
| Barrientos, J; Elstrom, R; Leonard, JP; Martin, P | 1 |
| Eckhardt, SG; Kaufman, SA; Morrow, M; Pitts, TM; Tentler, JJ | 1 |
| Chandra, J; Keating, MJ; Miller, CP; Palladino, M; Rudra, S; Wierda, WG | 1 |
| Assaf, C; Heider, U; Lamottke, B; Mieth, M; Moebs, M; Rademacher, J; Sezer, O; von Metzler, I | 1 |
| Chen, SJ; Chen, Z; Janin, A; Jiang, XX; Shen, ZX; Wang, L; Wu, WL; Yang, F; Zhang, QL; Zhang, YW; Zhao, WL | 1 |
| Carew, JS; Esquivel, JA; Giles, FJ; Huang, P; Kelly, K; Mahalingam, D; Medina, EC; Mita, AC; Mita, MM; Nawrocki, ST; Swords, R; Zhang, H | 1 |
| Badros, A; Baer, MR; Burger, AM; Egorin, MJ; Espinoza-Delgado, I; Goloubeva, O; Grant, S; Harris, C; Holleran, JL; Kolla, SS; Niesvizky, R; Philip, S; Wright, JJ; Zwiebel, J | 1 |
| Berenson, JR; Campbell, RA; Chen, H; Li, ZW; Sanchez, E; Shalitin, D; Steinberg, J | 1 |
| Beck, JF; Becker, S; Gressmann, S; Schmudde, M; Sonnemann, J; Wittig, S | 1 |
| Dasmahapatra, G; Dent, P; Fisher, RI; Friedberg, J; Grant, S; Kramer, L; Lembersky, D | 1 |
| Jagannath, S; Mazumder, A; Vesole, DH | 1 |
| Jones, DR; Liu, Y; Nagji, AS; Taylor, MD; Theodosakis, N | 1 |
| Cho, SH; Jones, DR; Lee, JK; Liu, Y; Nagji, AS | 1 |
| Jeong, KS; Kim, YT; Lee, JK; Lee, SH; Park, JK; Ryu, JK; Woo, SM; Yang, KY; Yoon, WJ; Yoon, YB | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Ciccarelli, B; Fulciniti, M; Gong, P; Hunter, Z; Liu, X; Maghsoudi, K; Munshi, NC; Patterson, CJ; Sun, JY; Treon, SP; Tseng, H; Xu, L; Yang, G; Zhou, Y; Zhu, B | 1 |
| Asano, T; Ito, K; Sato, A; Sumitomo, M | 1 |
| Ohmachi, K | 1 |
| Agostino, NR; DiDomenico, JD; Jane, EP; Pollack, IF; Premkumar, DR | 1 |
| Anderson, SK; Buckner, J; Friday, BB; Galanis, E; Geoffroy, F; Giannini, C; Gross, H; Jaeckle, K; Mazurczak, M; Pajon, E; Schwerkoske, J; Yu, C | 1 |
| de Lima, M; Koreth, J; Reddy, P | 1 |
| Asklund, T; Bergenheim, T; Hedman, H; Henriksson, R; Holmlund, C; Kvarnbrink, S; Wibom, C | 1 |
| De Becker, A; De Raeve, H; Van Camp, B; Van Riet, I; Vanderkerken, K; Xu, S | 1 |
| Ahern, CH; Ames, MM; Blaney, SM; Espinoza-Delgado, I; Horton, TM; Ingle, AM; McGovern, RM; Muscal, JA; Reid, JM; Thompson, PA; Weigel, BJ | 1 |
| Graef, T; Hardwick, JS; Hussein, M; Jagannath, S; Lupinacci, L; Schiller, GJ; Sobecks, RM; Weber, DM | 1 |
| Bao, Y; Burks, SG; Gillenwater, HH; Jones, DR; Kozower, BD; Moskaluk, CA; Olazagasti, J; Petroni, GR; Philips, J; Rehm, PK | 1 |
| Asano, T; Ito, K; Sato, A | 1 |
| Ogura, M | 1 |
| Barbone, D; Battula, S; Broaddus, VC; Bueno, R; Busacca, S; Cheung, P; Fennell, DA; Gray, SG; Longley, DB; Sugarbaker, DJ | 1 |
| Alsina, M; Anderson, KC; Bensinger, W; Biermann, JS; Cohen, AD; Devine, S; Djulbegovic, B; Faber, EA; Gasparetto, C; Hernandez-Illizaliturri, F; Huff, CA; Kassim, A; Krishnan, AY; Kumar, R; Liedtke, M; Meredith, R; Raje, N; Schriber, J; Shead, DA; Singhal, S; Somlo, G; Stockerl-Goldstein, K; Treon, SP; Weber, D; Yahalom, J; Yunus, F | 1 |
| Cao, Q; Miller, J; Warlick, ED | 1 |
| Chiang, AK; Ho, DN; Hui, KF; Lam, BH; Tsao, SW | 1 |
| Annereau, JP; Bailly, C; Bonnet, D; Brel, V; Créancier, L; Currie, E; Fournier, E; Gomes, B; Guilbaud, N; Guminski, Y; Kruczynski, A; Pillon, A; Vandenberghe, I | 1 |
| Ashlock, BM; Bhatt, S; Diaz, LA; Lossos, IS; Mesri, EA; Ramos, JC; Toomey, NL | 1 |
| Ahuja, HG; Blank, JH; Campbell, TC; Hernan, HR; Hoang, T; Huie, MS; Johnson, PH; Kim, K; Kirschling, RJ; Kolesar, JM; Larson, MM; Oettel, KR; Robinson, EG; Traynor, AM; Wims, ME; Zhang, C | 1 |
| McNeil, C | 1 |
| Che, XF; Kohno, N; Komatsu, S; Miyazawa, K; Moriya, S; Yokoyama, T | 1 |
| Alberti, D; Bailey, HH; Espinoza-Delgado, I; Hoang, T; Holen, KD; Kim, K; Kolesar, JM; Schelman, WR; Seo, S; Traynor, AM; Wilding, G; Wright, JJ | 1 |
| Anderson, KC; Blacklock, H; Dimopoulos, M; Eid, JE; Facon, T; Goldschmidt, H; Graef, T; Hajek, R; Houp, J; Hungria, V; Lonial, S; Palumbo, A; Qi, J; Rosinol, L; Siegel, DS; Spencer, A; Sun, L; Vuocolo, S; Williams, C | 1 |
| Alberti, D; Ames, MM; Attia, S; Bailey, HH; Eickhoff, J; Espinoza-Delgado, I; Hoang, T; Holen, KD; Jiang, Z; Kolesar, JM; Marnocha, R; McGovern, RM; Reid, JM; Schelman, WR; Traynor, AM; Wilding, G; Wright, JJ | 1 |
| Alberti, D; Ames, MM; Bailey, HH; Deming, DA; Eickhoff, J; Espinoza-Delgado, I; Kolesar, JM; Marnocha, R; McGovern, RM; Ninan, J; Reid, JM; Schelman, WR; Wilding, G; Wright, J | 1 |
| Johnson, DE; Kirk, CJ; Zang, Y | 1 |
| Ishitsuka, K; Katsuya, H; Kunami, N; Nogami, R; Tamura, K | 1 |
| Che, XF; Gotoh, A; Hiramoto, M; Hirota, A; Inazu, M; Kawai, Y; Kokuba, H; Komatsu, S; Miyazawa, K; Moriya, S; Yamasaki, K | 1 |
5 review(s) available for pyrazines and vorinostat
| Article | Year |
|---|---|
New agents in cancer clinical trials.
Topics: Antineoplastic Agents; Benzamides; Benzoquinones; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dioxoles; Enzyme Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; Isoquinolines; Lactams, Macrocyclic; Neoplasms; Piperazines; Pyrazines; Pyrimidines; Rifabutin; Stilbenes; Tetrahydrofolates; Tetrahydroisoquinolines; Trabectedin; Vorinostat | 2000 |
Targeted treatment and new agents in diffuse large B-cell lymphoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Delivery Systems; Humans; Hydroxamic Acids; Immunologic Factors; Indoles; Inhibitor of Apoptosis Proteins; Lymphoma, Large B-Cell, Diffuse; Microtubule-Associated Proteins; Neoplasm Proteins; Protease Inhibitors; Protein Kinases; Pyrazines; Survivin; TOR Serine-Threonine Kinases; Treatment Outcome; Vorinostat | 2008 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
[Present status and perspective of targeted therapy for B-cell lymphoma].
Topics: Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Drug Discovery; Flavonoids; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lenalidomide; Lymphoma, B-Cell; Molecular Targeted Therapy; Piperidines; Protease Inhibitors; Protein Kinase C; Protein Kinase C beta; Protein-Tyrosine Kinases; Pyrazines; Rituximab; Thalidomide; Vorinostat | 2011 |
Emerging therapies in hematopoietic stem cell transplantation.
Topics: Antineoplastic Agents; Azacitidine; Boronic Acids; Bortezomib; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Proteasome Inhibitors; Pyrazines; Vorinostat | 2012 |
11 trial(s) available for pyrazines and vorinostat
| Article | Year |
|---|---|
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hydroxamic Acids; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Vorinostat | 2009 |
Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Brain Neoplasms; Disease Progression; Female; Glioblastoma; Humans; Hydroxamic Acids; Male; Middle Aged; Pyrazines; Survival Analysis; Vorinostat | 2012 |
A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child, Preschool; Dose-Response Relationship, Drug; Endoplasmic Reticulum Chaperone BiP; Female; Humans; Hydroxamic Acids; Infant; Male; Maximum Tolerated Dose; Neoplasms; Pyrazines; Vorinostat; Young Adult | 2013 |
Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Drug Synergism; Female; Humans; Hydroxamic Acids; Male; Middle Aged; Multiple Myeloma; Pyrazines; Secondary Prevention; Vorinostat | 2012 |
Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Follow-Up Studies; Gene Expression Profiling; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoenzyme Techniques; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Prognosis; Proteasome Endopeptidase Complex; Pyrazines; Vorinostat | 2012 |
[Current development of new drugs in malignant lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Brentuximab Vedotin; Diphtheria Toxin; Drug Discovery; Everolimus; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Inotuzumab Ozogamicin; Interleukin-2; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Purine Nucleosides; Pyrazines; Pyrimidinones; Recombinant Fusion Proteins; Sirolimus; Thalidomide; Vorinostat | 2012 |
Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Middle Aged; Pyrazines; Treatment Outcome; Vorinostat | 2014 |
Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Boronic Acids; Bortezomib; Chromatin Immunoprecipitation; Cyclin-Dependent Kinase Inhibitor p21; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Leukocytes, Mononuclear; Neoplasms; Nuclear Receptor Subfamily 4, Group A, Member 1; Proto-Oncogene Proteins c-akt; Pyrazines; Time Factors; Transcription, Genetic; Vorinostat | 2013 |
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Double-Blind Method; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hydroxamic Acids; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Salvage Therapy; Survival Rate; Vorinostat | 2013 |
A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines; Vorinostat; Young Adult | 2013 |
A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines; Vorinostat | 2014 |
37 other study(ies) available for pyrazines and vorinostat
| Article | Year |
|---|---|
The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Butyrates; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protease Inhibitors; Pyrazines; Pyrimidines; Reactive Oxygen Species; Signal Transduction; Tumor Cells, Cultured; Vorinostat | 2003 |
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cytosol; Dose-Response Relationship, Drug; Enzyme Inhibitors; Free Radical Scavengers; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Intracellular Membranes; Membrane Glycoproteins; Membrane Potentials; Mitochondria; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Oxidative Stress; Oxygen; Protease Inhibitors; Proteins; Proteoglycans; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Sodium Oxybate; Syndecan-1; Syndecans; Tumor Suppressor Proteins; Vorinostat; X-Linked Inhibitor of Apoptosis Protein | 2004 |
Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Mitochondria; NF-kappa B; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Transcription, Genetic; Vorinostat | 2004 |
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Vorinostat; Xenograft Model Antitumor Assays | 2006 |
SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Caspase 8; Cell Line, Tumor; Fas Ligand Protein; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Membrane Potential, Mitochondrial; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Vorinostat | 2007 |
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Gene Expression Regulation, Leukemic; Genes, Wilms Tumor; Humans; Hydroxamic Acids; Leukemia, Megakaryoblastic, Acute; Leukemia, Myelomonocytic, Chronic; Megakaryocytes; Neoplasm Proteins; Pyrazines; Vorinostat; WT1 Proteins | 2008 |
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Cell Survival; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphoma, Mantle-Cell; NF-kappa B; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Treatment Outcome; Vorinostat | 2008 |
Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Nucleus Structures; Cycloheximide; Diploidy; Drug Synergism; Endoplasmic Reticulum; Fibroblasts; Histone Deacetylase 6; Histone Deacetylases; Humans; Hydroxamic Acids; Multiple Myeloma; Protein Biosynthesis; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrazines; RNA, Small Interfering; Vorinostat | 2008 |
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Hydroxamic Acids; Pyrazines; Signal Transduction; Vorinostat | 2009 |
Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.
Topics: Acetylation; Antioxidants; Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Drug Synergism; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoblotting; Immunoprecipitation; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Oxidative Stress; Protease Inhibitors; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Superoxides; Tumor Cells, Cultured; Vorinostat | 2009 |
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphoma, T-Cell, Cutaneous; Pharmacokinetics; Pyrazines; Reactive Oxygen Species; Vorinostat | 2009 |
The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Intracellular Signaling Peptides and Proteins; Jurkat Cells; Leukemia, T-Cell; Lymphoma, T-Cell; Mice; Mice, Nude; Neoplasm Proteins; Protease Inhibitors; Proteasome Inhibitors; Protein Kinases; Pyrazines; Signal Transduction; Vorinostat; Xenograft Model Antitumor Assays | 2009 |
Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Carcinoma; Cell Line, Tumor; Cell Survival; Chloroquine; Colonic Neoplasms; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; HT29 Cells; Humans; Hydroxamic Acids; Lysosomes; Mice; Mice, Inbred BALB C; Mice, Nude; Proteasome Endopeptidase Complex; Pyrazines; Superoxides; Ubiquitinated Proteins; Vorinostat; Xenograft Model Antitumor Assays | 2010 |
Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Myeloma Proteins; Neoplasm Proteins; Protease Inhibitors; Pyrazines; Vorinostat; Xenograft Model Antitumor Assays | 2010 |
The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Calreticulin; Caspase 8; Cell Line, Tumor; Child; Flow Cytometry; Fluorescent Antibody Technique; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Pyrazines; Vorinostat | 2010 |
The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Chymotrypsin; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; In Vitro Techniques; JNK Mitogen-Activated Protein Kinases; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Nude; Mitochondria; NF-kappa B; Oligopeptides; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Vorinostat; Xenograft Model Antitumor Assays | 2010 |
Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chronic Disease; Clinical Trials as Topic; Disease Progression; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Vorinostat | 2010 |
Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells.
Topics: Adenocarcinoma; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cadherins; Carcinoma, Squamous Cell; Cell Death; Cell Line, Tumor; Cell Movement; Epithelial Cells; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Mesoderm; Neoplasm Invasiveness; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA, Messenger; Spheroids, Cellular; Time Factors; Transfection; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Up-Regulation; Vorinostat | 2010 |
Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer.
Topics: Algorithms; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Gene Expression Profiling; Humans; Hydroxamic Acids; Lung Neoplasms; Multigene Family; Pyrazines; Vorinostat | 2010 |
Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Vorinostat; Xenograft Model Antitumor Assays | 2011 |
Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Line; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; p38 Mitogen-Activated Protein Kinases; Pyrazines; Stress, Physiological; Vorinostat; Waldenstrom Macroglobulinemia | 2011 |
Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.
Topics: Acetylation; Acetyltransferases; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Drug Synergism; Drug Therapy, Combination; Flow Cytometry; Fluorine Radioisotopes; Histones; Humans; Hydroxamic Acids; Kidney Neoplasms; Mice; Pyrazines; Tumor Cells, Cultured; Ubiquitination; Vorinostat | 2012 |
Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Cell Line, Tumor; Central Nervous System Neoplasms; Cytochromes c; DNA Damage; Glioblastoma; Glioma; Histones; Humans; Hydroxamic Acids; Membrane Potential, Mitochondrial; Membrane Proteins; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Phosphorylation; Proteasome Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Tumor Cells, Cultured; Vorinostat | 2013 |
Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Drug Synergism; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplastic Stem Cells; Neural Stem Cells; Phenylbutyrates; Pyrazines; Valproic Acid; Vorinostat | 2012 |
In vitro expanded bone marrow-derived murine (C57Bl/KaLwRij) mesenchymal stem cells can acquire CD34 expression and induce sarcoma formation in vivo.
Topics: Animals; Antigens, CD34; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Transformation, Neoplastic; Female; Hydroxamic Acids; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Neoplastic Stem Cells; Pyrazines; Receptors, Notch; Sarcoma; Vorinostat; Wnt Proteins | 2012 |
Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells.
Topics: Animals; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Humans; Hydroxamic Acids; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Prostatic Neoplasms; Pyrazines; Random Allocation; RNA, Small Interfering; Sensitivity and Specificity; Ubiquitinated Proteins; Vorinostat; Xenograft Model Antitumor Assays | 2012 |
Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Hydroxamic Acids; Membrane Proteins; Mesothelioma; Myeloid Cell Leukemia Sequence 1 Protein; Pemetrexed; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Spheroids, Cellular; Up-Regulation; Vorinostat | 2012 |
Multiple myeloma, version 1.2013.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Humans; Hydroxamic Acids; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Vorinostat | 2013 |
Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazines; Treatment Outcome; Vorinostat | 2013 |
Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Herpesvirus 4, Human; Heterografts; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mice; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Pyrazines; Reactive Oxygen Species; Signal Transduction; Tumor Burden; Virus Replication; Vorinostat | 2013 |
F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cytarabine; Deoxycytidine; Doxorubicin; Fetal Blood; Flow Cytometry; Gemcitabine; Humans; Hydroxamic Acids; Immunoenzyme Techniques; Interleukin Receptor Common gamma Subunit; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Podophyllotoxin; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Vorinostat; Xenograft Model Antitumor Assays | 2013 |
Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Synergism; HEK293 Cells; Herpesviridae Infections; Herpesvirus 8, Human; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Lymphoma, Primary Effusion; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondria; Proteasome Inhibitors; Proto-Oncogene Proteins c-myc; Pyrazines; Tumor Suppressor Protein p53; Virus Latency; Virus Replication; Vorinostat; Xenograft Model Antitumor Assays | 2013 |
Preventing graft-versus-host disease: transplanters glimpse hope beyond immunosuppressants.
Topics: Acute Disease; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Chronic Disease; Clinical Trials as Topic; Cyclohexanes; Cyclophosphamide; Cyclosporine; Evidence-Based Medicine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Immunosuppressive Agents; Maraviroc; Methotrexate; Pentostatin; Peripheral Blood Stem Cell Transplantation; Pyrazines; Quality of Life; Tacrolimus; Triazoles; Vorinostat | 2013 |
Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells.
Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Clarithromycin; Drug Screening Assays, Antitumor; Endoplasmic Reticulum Stress; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Inclusion Bodies; Intracellular Space; Mice; Proteolysis; Pyrazines; Transcription Factor CHOP; Vorinostat | 2013 |
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Membrane Proteins; Mitochondrial Proteins; Oligopeptides; Proteasome Inhibitors; Pyrazines; Vorinostat | 2014 |
Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia-Lymphoma, Adult T-Cell; Nitrophenols; Piperazines; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides; Vorinostat | 2014 |
Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress‑mediated cell death in multiple myeloma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Clarithromycin; Drug Synergism; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Histone Deacetylase 6; Histone Deacetylases; Humans; Hydroxamic Acids; Mice; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Vorinostat | 2015 |